{"id":133866,"date":"2026-06-30T08:21:12","date_gmt":"2026-06-30T08:21:12","guid":{"rendered":"https:\/\/www.europesays.com\/cz\/133866\/"},"modified":"2026-06-30T08:21:12","modified_gmt":"2026-06-30T08:21:12","slug":"prepise-evropa-budoucnost-mediciny-novy-plan-ma-porazit-byrokracii-a-zrychlit-schvalovani-leku","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/cz\/133866\/","title":{"rendered":"P\u0159ep\u00ed\u0161e Evropa budoucnost medic\u00edny? Nov\u00fd pl\u00e1n m\u00e1 porazit byrokracii a zrychlit schvalov\u00e1n\u00ed l\u00e9k\u016f"},"content":{"rendered":"<p>Evropa nesm\u00ed v biotechnologick\u00e9m z\u00e1vod\u011b zaspat. Spole\u010dn\u00e1 zpr\u00e1va v\u00fdbor\u016f Evropsk\u00e9ho parlamentu SANT a ITRE k Aktu o biotechnologi\u00edch proto navrhuje zkr\u00e1cen\u00ed schvalovac\u00edch lh\u016ft pro strategick\u00e9 projekty a\u017e na \u010dty\u0159i m\u011bs\u00edce, vznik specializovan\u00e9ho unijn\u00edho fondu pro p\u0159ekon\u00e1n\u00ed kritick\u00fdch f\u00e1z\u00ed financov\u00e1n\u00ed a t\u011bsn\u011bj\u0161\u00ed propojen\u00ed v\u011bdy s v\u00fdrobou.<\/p>\n<p>Spoluzpravodaj za v\u00fdbor SANT Vytenis Andriukaitis p\u0159edstavil spole\u010dnou zpr\u00e1vu, kter\u00e1 obsahuje celkem 390 pozm\u011b\u0148ovac\u00edch n\u00e1vrh\u016f. Podle n\u011bj mus\u00ed b\u00fdt akt vn\u00edm\u00e1n jako komplexn\u00ed evropsk\u00fd r\u00e1mec, nikoli jako \u00fazce zam\u011b\u0159en\u00fd odv\u011btvov\u00fd n\u00e1stroj. Hlavn\u00edm probl\u00e9mem sou\u010dasn\u00e9 Evropy je podle n\u011bj pomalost, rozt\u0159\u00ed\u0161t\u011bnost a nep\u0159edv\u00eddatelnost. Tyto faktory odrazuj\u00ed v\u011bdce i investory a v kone\u010dn\u00e9m d\u016fsledku \u0161kod\u00ed pacient\u016fm.<\/p>\n<p>N\u00e1vrh proto p\u0159ich\u00e1z\u00ed s u\u017e\u0161\u00edm propojen\u00edm nemocnic, univerzit, biobank a genomick\u00fdch iniciativ do jednoho funguj\u00edc\u00edho ekosyst\u00e9mu. V\u00fdznamnou roli m\u00e1 hr\u00e1t pos\u00edlen\u00ed Evropsk\u00e9 agentury pro l\u00e9\u010div\u00e9 p\u0159\u00edpravky (EMA) a vytvo\u0159en\u00ed specializovan\u00e9ho v\u00fdboru expert\u016f pro klinick\u00e9 studie, kter\u00fd by m\u011bl schvalovac\u00ed procesy z\u00e1sadn\u011b zrychlit.<\/p>\n<p>\u201eEvropa mus\u00ed z\u016fstat centrem excelence v biotechnologi\u00edch. Samotn\u00e1 excelence ale nesta\u010d\u00ed. Mus\u00edme b\u00fdt schopn\u00ed p\u0159etavit v\u00fdzkum do inovac\u00ed, inovace do v\u00fdroby a v\u00fdrobu do skute\u010dn\u00e9ho p\u0159\u00edstupu pro v\u0161echny pacienty ve v\u0161ech 27 \u010dlensk\u00fdch st\u00e1tech,\u201c prohl\u00e1sil Andriukaitis. \u201eEvropsk\u00fd Akt o biotechnologi\u00edch p\u0159edstavuje p\u0159\u00edle\u017eitost, kter\u00e1 se objev\u00ed jednou za generaci, jak vr\u00e1tit Evropu na mapu jako glob\u00e1ln\u00ed c\u00edl pro biotechnologick\u00e9 inovace, investice a v\u00fdvoj terapi\u00ed,\u201c dodal.<\/p>\n<p>Rychlej\u0161\u00ed povolen\u00ed a boj s \u201e\u00fadol\u00edm smrti\u201c<\/p>\n<p>Samotn\u00fd text n\u00e1vrhu zpr\u00e1vy p\u0159in\u00e1\u0161\u00ed \u0159adu legislativn\u00edch \u00faprav oproti p\u016fvodn\u00edmu n\u00e1vrhu Evropsk\u00e9 komise. Jednou z nejv\u00fdznamn\u011bj\u0161\u00edch zm\u011bn je roz\u0161\u00ed\u0159en\u00ed p\u016fsobnosti aktu z \u010dist\u011b \u201ezdravotnick\u00fdch biotechnologi\u00ed\u201c na obecn\u011bj\u0161\u00ed podporu biotechnologick\u00e9ho a biov\u00fdrobn\u00edho sektoru.<\/p>\n<p>Zpr\u00e1va nav\u00edc zav\u00e1d\u00ed koncept takzvan\u00fdch Panevropsk\u00fdch strategick\u00fdch projekt\u016f s vysok\u00fdm dopadem. Ty maj\u00ed usnadnit p\u0159eshrani\u010dn\u00ed spolupr\u00e1ci a zajistit, aby siln\u00e9 projekty v jednom st\u00e1t\u011b mohly z\u00edskat strategick\u00fd status bez nutnosti vytv\u00e1\u0159et um\u011bl\u00e9 mezin\u00e1rodn\u00ed konstrukce. Z\u00e1sadn\u00ed \u00falevou pro pr\u016fmysl m\u00e1 b\u00fdt tak\u00e9 radik\u00e1ln\u00ed zkr\u00e1cen\u00ed lh\u016ft pro schvalovac\u00ed procesy \u2013 u strategick\u00fdch projekt\u016f se zkracuje z deseti na pouh\u00fdch \u0161est m\u011bs\u00edc\u016f, u projekt\u016f s vysok\u00fdm dopadem na \u010dty\u0159i m\u011bs\u00edce.<\/p>\n<p>Nem\u00e9n\u011b d\u016fle\u017eitou kapitolou je financov\u00e1n\u00ed. Europoslanci v textu reaguj\u00ed na pal\u010div\u00fd probl\u00e9m, kdy firmy v Evrop\u011b sice dok\u00e1\u017eou projekty odstartovat, ale kv\u016fli nedostatku kapit\u00e1lu pro pozdn\u00ed f\u00e1ze v\u00fdvoje odch\u00e1zej\u00ed do z\u00e1mo\u0159\u00ed.<\/p>\n<p>    Mohlo by v\u00e1s zaj\u00edmat<\/p>\n<p>        <a href=\"https:\/\/www.zdravotnickydenik.cz\/2026\/06\/paliativni-pece-plan-vlada-ministerstvo-zdravotnictvi\/\" class=\"relative block overflow-hidden rounded-lg group aspect-[3\/2] md:aspect-video min-w-[88px] sm:min-w-[175px] lg:min-w-[225px]\" aria-label=\"\u010d\u00edst v\u00edce\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n                        <img loading=\"lazy\" decoding=\"async\" width=\"384\" height=\"256\" src=\"https:\/\/www.europesays.com\/cz\/wp-content\/uploads\/2026\/06\/hand-in-hand-1686811_960_720-pixabay.jpg\" class=\"absolute object-cover w-full h-full group-hover:scale-105 transition-all\" alt=\"\"\/><br \/>\n                        <\/a><\/p>\n<p>Zpr\u00e1va proto navrhuje z\u0159\u00edzen\u00ed Evropsk\u00e9ho fondu pro biotechnologick\u00e9 \u0161k\u00e1lov\u00e1n\u00ed. Tento n\u00e1stroj, funguj\u00edc\u00ed na principu fondu fond\u016f, m\u00e1 kombinovat ve\u0159ejn\u00e9 zdroje EU a Evropsk\u00e9 investi\u010dn\u00ed banky s dlouhodob\u00fdm soukrom\u00fdm kapit\u00e1lem (nap\u0159\u00edklad penzijn\u00edmi fondy), a pomoci tak inovativn\u00edm start-up\u016fm p\u0159ekonat kritick\u00e9 obdob\u00ed r\u016fstu, kter\u00e9mu se v byznysov\u00e9 hant\u00fdrce p\u0159ezd\u00edv\u00e1 \u201e\u00fadol\u00ed smrti\u201c.<\/p>\n<p>Biotechnologie jako geopolitick\u00e1 zbra\u0148<\/p>\n<p>Pond\u011bln\u00ed spole\u010dn\u00e9 jedn\u00e1n\u00ed uk\u00e1zalo, \u017ee \u00e9ra, kdy byly biotechnologie vn\u00edm\u00e1ny \u010dist\u011b p\u0159es optiku zdravotn\u00ed politiky, definitivn\u011b skon\u010dila. P\u0159edseda v\u00fdboru SANT Adam Jarubas zd\u016fraznil, \u017ee biotechnologie a biologick\u00e1 v\u00fdroba pat\u0159\u00ed mezi nejrychleji rostouc\u00ed hospod\u00e1\u0159sk\u00e1 odv\u011btv\u00ed v EU. Jsou proto naprosto kl\u00ed\u010dov\u00e9 pro strategickou autonomii a hospod\u00e1\u0159skou bezpe\u010dnost unie.<\/p>\n<p>Belgick\u00fd europoslanec Wouter Beke, kter\u00fd zpr\u00e1vu spoluvypracoval za v\u00fdbor ITRE, podpo\u0159il tento pohled tvrd\u00fdmi daty. Evropsk\u00fd biotechnologick\u00fd sektor vygeneroval v roce 2022 HDP ve v\u00fd\u0161i 38 miliard eur a podpo\u0159il v\u00edce ne\u017e 913 tis\u00edc pracovn\u00edch m\u00edst. Varoval v\u0161ak, \u017ee Evropa ztr\u00e1c\u00ed pod\u00edl na trhu ve v\u0161ech f\u00e1z\u00edch \u2013 od rizikov\u00e9ho kapit\u00e1lu p\u0159es klinick\u00e9 studie a\u017e po komercializaci.<\/p>\n<p>\u201eBiotechnologie nejsou prost\u011b jen dal\u0161\u00edm pr\u016fmyslov\u00fdm odv\u011btv\u00edm. Jsou budoucnost\u00ed medic\u00edny. Dnes je v\u00edce ne\u017e polovina v\u0161ech nov\u00fdch l\u00e9k\u016f zalo\u017eena na biotechnologi\u00edch,\u201c upozornil Beke. Jde o pr\u016flomov\u00e1 \u0159e\u0161en\u00ed od genov\u00fdch a bun\u011b\u010dn\u00fdch terapi\u00ed a\u017e po personalizovanou l\u00e9\u010dbu. \u201eV uplynul\u00fdch desetilet\u00edch Evropa p\u0159istupovala k biotechnologi\u00edm prim\u00e1rn\u011b jako k ot\u00e1zce zdravotn\u00ed politiky. To byla chyba. Biotechnologie se staly hluboce geopolitickou z\u00e1le\u017eitost\u00ed,\u201c dodal.<\/p>\n","protected":false},"excerpt":{"rendered":"Evropa nesm\u00ed v biotechnologick\u00e9m z\u00e1vod\u011b zaspat. Spole\u010dn\u00e1 zpr\u00e1va v\u00fdbor\u016f Evropsk\u00e9ho parlamentu SANT a ITRE k Aktu o biotechnologi\u00edch&hellip;\n","protected":false},"author":2,"featured_media":133867,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[3],"tags":[27028,24812,373,109,108,106,249,2154,1615,36096,4912,1617,31198],"class_list":["post-133866","post","type-post","status-publish","format-standard","has-post-thumbnail","category-evropa","tag-akt-o-biotechnologiich","tag-biotechnologie","tag-eu","tag-europa","tag-europe","tag-evropa","tag-evropska-komise","tag-evropsky-parlament","tag-inovace","tag-itre","tag-konkurenceschopnost","tag-leky","tag-sant"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@cz\/116838091131788490","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/133866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/comments?post=133866"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/posts\/133866\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media\/133867"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/media?parent=133866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/categories?post=133866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/cz\/wp-json\/wp\/v2\/tags?post=133866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}